Related Experiment Video
Updated: Dec 19, 2025
Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells
Published on: April 7, 2023
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma
Shambavi Richard1, Joshua Richter1, Sundar Jagannath1
1Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York 10029, USA.
Abstract:
The progression of multiple myeloma is accompanied by complex cytogenetic and epigenetic alterations that include mutation or functional inactivation of tumor suppressor proteins and overexpression of oncoproteins. Patients whose myeloma is refractory to the three major classes of drugs including immunomodulatory agents, proteasome inhibitors and anti-CD38 monoclonal antibodies have a very poor prognosis. Drugs with novel mechanisms of action that can bypass resistance mechanisms are sorely needed for this group of patients. Selinexor represents a novel, oral agent with an innovative mechanism of action that offers a significant therapeutic advance in this group of heavily treated patients. Moreover, this novel mechanism may provide additional options for patients with less refractory disease.
Insights
Selinexor offers a new oral treatment option for patients with advanced multiple myeloma who are resistant to current therapies. This drug
Area of Science:
- Oncology
- Hematology
- Molecular Biology
Background:
- Multiple myeloma progression involves genetic and epigenetic changes, including tumor suppressor inactivation and oncoprotein overexpression.
- Patients with myeloma refractory to immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies face a poor prognosis.
- Novel therapies are crucial for overcoming drug resistance in multiple myeloma.
Purpose of the Study:
- To evaluate selinexor, a novel oral agent, for treating patients with heavily pretreated and refractory multiple myeloma.
- To explore the potential of selinexor's innovative mechanism of action in overcoming existing resistance pathways.
- To assess selinexor as a therapeutic option for patients with less refractory multiple myeloma.
Main Methods:
- Clinical evaluation of selinexor in patients with advanced multiple myeloma.
- Assessment of selinexor's efficacy in patients refractory to standard therapies.
- Analysis of selinexor's mechanism of action in bypassing resistance.
Main Results:
- Selinexor demonstrates significant therapeutic advance in heavily treated patients with refractory multiple myeloma.
- The novel mechanism of action of selinexor provides a promising option for overcoming drug resistance.
- Selinexor may offer additional treatment avenues for patients with less refractory disease.
Conclusions:
- Selinexor represents a significant therapeutic advance for patients with refractory multiple myeloma.
- Its innovative mechanism of action addresses unmet needs in heavily pretreated patients.
- Selinexor holds promise for expanding treatment options in multiple myeloma management.
More Related Videos
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
07:02Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
Published on: May 11, 2018
